Trastuzumab use beyond progression on previous trastuzumab treatment in HER-2 positive metastatic breast cancer

被引：0
|
作者：
Hutka, Margaret M. [1 ]
Kolosza, Zofia [1 ]
Utracka-Hutka, Beata [1 ]
机构：
[1] MSC Mem Canc Ctr, Inst Oncol, Gliwice, Poland
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [1] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [2] Trastuzumab beyond progression in HER2-positive metastatic breast cancer
    Al-Naqqash, Manwar
    Jasim Al-Serarati, Waleed
    Farooq Kareem, Tara
    BREAST JOURNAL, 2021, 27 (03): : 297 - 299
  • [3] Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
    Park, I. H.
    Ro, J.
    Lee, K. S.
    Nam, B. H.
    Kwon, Y.
    Shin, K. H.
    ANNALS OF ONCOLOGY, 2009, 20 (01) : 56 - 62
  • [4] Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
    Izzet Dogan
    Esra Aydin
    Nijat Khanmammadov
    Nail Paksoy
    Pinar Saip
    Adnan Aydiner
    Scientific Reports, 13
  • [5] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [6] Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
    Dogan, Izzet
    Aydin, Esra
    Khanmammadov, Nijat
    Paksoy, Nail
    Saip, Pinar
    Aydiner, Adnan
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [7] HER-2-positive metastatic breast cancer: trastuzumab and beyond
    Metro, Giulio
    Mottolese, Marcella
    Fabi, Alessandra
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2583 - 2601
  • [8] Activity of trastuzumab beyond disease progression in HER-2 positive metastatic breast cancer: Results from a combined analysis
    Metro, Giulio
    Mottolese, Marcella
    Giannarelli, Diana
    Ferretti, Gianluigi
    Cognetti, Francesco
    Papaldo, Paola
    Felici, Alessandra
    Carlini, Paolo
    Cianciulli, Anna M.
    Fabi, Alessandra
    ANNALS OF ONCOLOGY, 2007, 18 : 162 - 162
  • [9] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [10] Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer
    Pusztai, L
    Esteva, FJ
    CANCER INVESTIGATION, 2006, 24 (02) : 187 - 191
12345